VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has advanced its VXA-222 bispecific antibody-drug conjugate program into the next stage of development. The company announced that it has completed the initial phase of its collaboration with OmniAb, a provider of transgenic animal platforms for antibody discovery, and will now engineer the final VXA-222 candidate and conduct preclinical validation to determine the program's next steps.
VXA-222 employs an "AND-gate" approach designed to recognize two tumor-associated antigens simultaneously before delivering its therapeutic payload. This dual-targeting strategy is intended to enhance specificity and reduce off-target effects, potentially improving the therapeutic index compared to conventional ADCs. By requiring the presence of two antigens on the tumor cell surface, the therapy aims to more precisely target cancer cells while sparing healthy tissue.
The advancement of VXA-222 marks a significant milestone for VERAXA as it transitions from discovery to preclinical development. The company will leverage its proprietary antibody engineering, linker, and conjugation technologies to construct the final candidate. This move underscores VERAXA's commitment to building a diversified oncology pipeline that spans bispecific T-cell engagers, ADCs, and other engineered antibody formats.
In parallel, VERAXA has filed its first patents related to its BiTAC-TCE and BiTAC-ADC platforms, while expanding protection around antibody conjugation and payload technologies. This intellectual property strategy is crucial for safeguarding the company's innovations and establishing a competitive moat in the rapidly evolving field of cancer immunotherapy.
The news comes as VERAXA continues to make strides in the development of next-generation cancer therapies. The company's focus on bispecific antibodies and ADCs positions it to address significant unmet medical needs in oncology. With a robust pipeline and a growing IP estate, VERAXA is poised to make meaningful contributions to the fight against cancer.
According to a Yahoo Finance report, VERAXA will now take the antibody binders generated through the OmniAb collaboration and use its own technologies to construct the final VXA-222 candidate. This collaboration has provided access to a diverse array of antibodies, which VERAXA will optimize for therapeutic efficacy.
The advancement of VXA-222 is a testament to the company's progress and its ability to execute on its strategic goals. As VERAXA moves forward, investors and stakeholders will be watching closely for updates on preclinical data and the program's progression toward clinical trials.
